{
    "root": "15c77ad7-7edc-4c36-ba3f-3ef05dfb12dc",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Venlafaxine Hydrochloride",
    "value": "20250227",
    "ingredients": [
        {
            "name": "ETHYLCELLULOSE (20 MPA.S)",
            "code": "BJG0S321QY",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11228"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "VENLAFAXINE HYDROCHLORIDE",
            "code": "7D7RX5A8MO",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9944"
        }
    ],
    "indications": {
        "text": "venlafaxine hydrochloride extended-release capsules indicated adults treatment : \u2022 major depressive disorder ( mdd ) [ ( 14.1 ) ] \u2022 generalized anxiety disorder ( gad ) [ ( 14.2 ) ] \u2022 social anxiety disorder ( sad ) [ ( 14.3 ) ] \u2022 panic disorder ( pd ) [ ( 14.4 ) ]",
        "doid_entities": [
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            },
            {
                "text": "generalized anxiety disorder (DOID:14320)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_14320"
            },
            {
                "text": "anxiety (DOID:2030)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2030"
            },
            {
                "text": "panic disorder (DOID:594)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_594"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "indication starting dose target dose maximum dose mdd ( 2.2 ) 37.5 75 mg/day 75 mg/day 225 mg/day gad ( 2.3 ) 37.5 75 mg/day 75 mg/day 225 mg/day sad ( 2.4 ) 75 mg/day 75 mg/day 75 mg/day pd ( 2.5 ) 37.5 mg/day 75 mg/day 225 mg/day \u2022 take daily food . capsules taken whole ; divide , crush , chew , dissolve ( 2.1 ) . \u2022 discontinuing treatment , reduce dose gradually ( 2.10 , 5.7 ) . \u2022 renal impairment : reduce total daily dose 25 % 50 % patients renal impairment . reduce total daily dose 50 % patients undergoing dialysis severe renal impairment ( 2.9 ) . \u2022 hepatic impairment : reduce daily dose 50 % patients mild moderate hepatic impairment . patients severe hepatic impairment hepatic cirrhosis , may necessary reduce dose 50 % ( 2.8 ) .",
        "doid_entities": [
            {
                "text": "cirrhosis (DOID:5082)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5082"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe hepatic impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            },
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "venlafaxine hydrochloride extended-release capsules , usp available follows : \u2022 75 mg capsules size `` 1 `` peach colour hard gelatin capsules filled white white pellets imprinted `` g `` cap , `` 75 `` body red ink . bottles 30 ndc 68788-8837-3 bottles 60 ndc 68788-8837-6 bottles 90 ndc 68788-8837-9 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "venlafaxine hydrochloride extended-release capsules contraindicated patients : \u2022with known hypersensitivity venlafaxine hydrochloride , desvenlafaxine succinate excipients formulation [ ( 6.2 ) ] . \u2022taking , within 14 days stopping , maois ( including maois linezolid intravenous methylene blue ) risk serotonin syndrome [ ( 2.11 ) , ( 5.2 ) , ] .",
    "indications_original": "Venlafaxine hydrochloride extended-release capsules are indicated in adults for the treatment of:    \u2022 Major Depressive Disorder (MDD)    [    see Clinical Studies (14.1)]   \n                      \u2022 Generalized Anxiety Disorder (GAD)    [    see Clinical Studies (14.2)]   \n                      \u2022 Social Anxiety Disorder (SAD)    [    see Clinical Studies (14.3)]   \n                      \u2022 Panic Disorder (PD)    [    see Clinical Studies (14.4)]",
    "contraindications_original": "Indication Starting Dose Target Dose Maximum Dose MDD ( 2.2 ) 37.5 to 75 mg/day 75 mg/day 225 mg/day GAD ( 2.3 ) 37.5 to 75 mg/day 75 mg/day 225 mg/day SAD ( 2.4 ) 75 mg/day 75 mg/day 75 mg/day PD ( 2.5 ) 37.5 mg/day 75 mg/day 225 mg/day \u2022 Take once daily with food. Capsules should be taken whole; do not divide, crush, chew, or dissolve ( 2.1 ). \u2022 When discontinuing treatment, reduce the dose gradually ( 2.10 , 5.7 ). \u2022 Renal impairment: reduce the total daily dose by 25% to 50% in patients with renal impairment. Reduce the total daily dose by 50% or more in patients undergoing dialysis or with severe renal impairment ( 2.9 ). \u2022 Hepatic impairment: reduce the daily dose by 50% in patients with mild to moderate hepatic impairment. In patients with severe hepatic impairment or hepatic cirrhosis, it may be necessary to reduce the dose by more than 50% ( 2.8 ).",
    "warningsAndPrecautions_original": "Venlafaxine hydrochloride extended-release capsules, USP are available as follows:\n                  \n                      \u2022 75 mg capsules are size \"1\" peach colour hard gelatin capsules filled with white to off white pellets and imprinted with \"G\" on cap, \"75\" on body with red ink.  \n                  Bottles of 30          NDC 68788-8837-3\n                  Bottles of 60          NDC 68788-8837-6\n                  Bottles of 90          NDC 68788-8837-9\n                  \n                     Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Venlafaxine hydrochloride extended-release capsules are contraindicated in patients:\n                  \n                     \n                        \u2022with known hypersensitivity to venlafaxine hydrochloride, desvenlafaxine succinate or to any excipients in the formulation     [see      Adverse Reactions (6.2)].    \n                     \n                     \n                        \u2022taking, or within 14 days of stopping, MAOIs (including the MAOIs linezolid and intravenous methylene blue) because of the risk of serotonin syndrome     [see      Dosage and Administration (2.11),\n                           Warnings and Precautions (5.2), and      \n                        ].",
    "drug": [
        {
            "name": "Venlafaxine Hydrochloride",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_9944"
        }
    ]
}